|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7105530||NOVARTIS||Pyrimidineamines as angiogenesis modulators|| |
(24 days from now)
Votrient is owned by Novartis.
Votrient contains Pazopanib Hydrochloride.
Votrient has a total of 1 drug patent out of which 0 drug patents have expired.
Votrient was authorised for market use on 19 October, 2009.
Votrient is available in tablet;oral dosage forms.
The generics of Votrient are possible to be released after 19 October, 2023.
Market Authorisation Date: 19 October, 2009
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic